Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04730349 · ClinicalTrials.gov registry record · Phase 1
A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer
A Phase 1 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT04730349 is a Phase 1 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 15 participants.
The verdict
NCT04730349, a Phase 1 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to first, in Part A, assess the safety, tolerability and drug levels of Bempegaldesleukin (BEMPEG) in combination with nivolumab and then, in Part B, to estimate the preliminary efficacy in children, adolescents and young adults with recurrent or treatment-resistant cancer.
Interventions
- BIOLOGICAL Nivolumab
- BIOLOGICAL NKTR-214
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2021-06-03 |
| Est. Completion | 2022-06-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04730349
The ClinicalTrials.gov registry entry for NCT04730349 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 15 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Nivolumab is the first listed.
NCT04730349 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04730349 about?
NCT04730349 is a clinical study titled "A Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant Cancer". The purpose of this study is to first, in Part A, assess the safety, tolerability and drug levels of Bempegaldesleukin (BEMPEG) in combination with nivolumab and then, in Part B, to estimate the preliminary efficacy in children, adolescents and young adults with recurrent or treatment-resistant canc...
What is the current status of trial NCT04730349?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2021-06-03. Estimated completion is 2022-06-22.
What interventions are being tested in trial NCT04730349?
The interventions under investigation include: Nivolumab (BIOLOGICAL), NKTR-214 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04730349?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.